Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.
This combination of email and password didn't match our records. Your account might not be activated. If so, please click on the link we sent you via email. You can also request a password reset or a new activation email using the links below.
DANO cae c. -3% (-4% vs Euro STOXX 50) tras conocerse que ha ampliado la retirada de lotes de sus fórmulas de alimentación infantil Aptamil y Cow & Gate en Reino Unido
4Q'25 vs. 4Q'24 Results EBITDA: US$ 1.59 Bn (-3.7% vs. -8.6% BS(e) and -7.6% consensus); Net Profit: US$ 654 M (+61.9% vs. -24.0% BS(e) and -21.0% consensus); FY2025 vs. FY2024 Results EBITDA: US$ 6.54 Bn (-7.3% vs. -8.4% BS(e) and -8.2% consensus); Net Profit: US$ 3.15 Bn (+135.4% vs. +109.5% BS(e) and +110.4% consensus).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.